Mounjaro Cost in New Hampshire: Prices, Insurance, and Savings in 2026

What Mounjaro Costs at New Hampshire Pharmacies in 2026

The retail cash price for brand-name Mounjaro at New Hampshire pharmacies sits at $1,023 per month in 2026, matching Eli Lilly's national list price. This price applies across all dose strengths, from the 2.5 mg starter pen to the maximum 15 mg pen. Patients paying out of pocket will find minimal variation between chains and independents statewide.

Tirzepatide, the active ingredient in Mounjaro, is a dual GIP/GLP-1 receptor agonist that earned FDA approval for type 2 diabetes in May 2022. In the SURPASS-2 trial (N=1,879), tirzepatide 15 mg reduced HbA1c by 2.58% compared with 1.86% for semaglutide 1 mg over 40 weeks. Weight loss differences were also significant: participants on tirzepatide 15 mg lost 12.4 kg versus 6.2 kg on semaglutide [1].

Prices in New Hampshire do not differ meaningfully from neighboring New England states. Vermont, Maine, and Massachusetts report the same $1,023 list price at retail. The real cost variation comes down to insurance status, coupon eligibility, and whether a patient qualifies for compounded tirzepatide.

Pharmacy discount aggregators like GoodRx or RxSaver sometimes shave $50 to $100 off the cash price, but these discounts fluctuate. They cannot be combined with insurance or the manufacturer savings card.

New Hampshire Medicaid and Mounjaro Coverage

New Hampshire Medicaid does not cover Mounjaro for weight management. Coverage for the type 2 diabetes indication is restricted and requires prior authorization, with formulary placement varying by managed care organization.

The state's Medicaid program, NH Medicaid Care Management, contracts with two managed care organizations. Both plans classify GLP-1 receptor agonists as non-preferred agents for diabetes, requiring step therapy through metformin and often a sulfonylurea before approval. Weight-loss prescriptions are excluded entirely under New Hampshire's Medicaid pharmacy benefit.

This exclusion aligns with a broader national pattern. According to a KFF analysis, fewer than half of state Medicaid programs covered any anti-obesity medication as of late 2024. The Treat and Reduce Obesity Act, if passed at the federal level, would mandate Medicare Part D coverage for anti-obesity drugs, but it would not directly compel state Medicaid programs to follow [2].

For New Hampshire Medicaid enrollees with type 2 diabetes who need a GIP/GLP-1 agonist, an endocrinologist's letter documenting prior medication failures can strengthen the prior authorization request. Approval rates improve when the prescriber specifies HbA1c targets not met on first-line therapy and documents contraindications to alternatives.

Commercial Insurance Coverage in New Hampshire

Most major commercial insurers in New Hampshire cover Mounjaro for type 2 diabetes, though nearly all require prior authorization and step therapy. Coverage for weight management (off-label for Mounjaro, on-label for Zepbound) is less consistent and plan-dependent.

Anthem Blue Cross Blue Shield, the dominant commercial carrier in the state, covers Mounjaro on its preferred specialty tier for members with a documented HbA1c of 7.0% or higher who have tried metformin for at least 90 days. Copays on specialty tiers typically range from $75 to $150 per month before any manufacturer offset.

Harvard Pilgrim Health Care and Cigna plans sold in New Hampshire follow similar step-therapy protocols. Cigna's 2026 formulary lists tirzepatide as a non-preferred brand, meaning higher cost-sharing unless the prescriber completes a coverage exception form.

Employer-sponsored plans vary widely. Self-funded employers can choose to exclude or include GLP-1 coverage for obesity. A 2024 survey by the International Foundation of Employee Benefit Plans found that roughly 40% of large employers covered at least one GLP-1 for weight loss, up from 26% the prior year [3].

Patients should call the number on their insurance card and ask specifically about tirzepatide by name, because Mounjaro and Zepbound contain the same molecule but are billed under different NDC codes. A plan that covers Zepbound for obesity may deny Mounjaro used off-label for the same purpose.

How the Eli Lilly Savings Card Works in New Hampshire

The Eli Lilly Mounjaro Savings Card can reduce out-of-pocket costs to as little as $25 per monthly fill for commercially insured patients. It is not valid for patients on government insurance, including Medicaid, Medicare, or Tricare.

Eligibility requirements are straightforward. The patient must have commercial insurance that covers Mounjaro, and the savings card covers the difference between the patient's copay and $25, up to a maximum benefit of $150 per fill or $1,800 per calendar year. If the plan's copay exceeds $175, the patient pays the remainder.

Activation takes about two minutes on Lilly's website. The card generates a BIN, PCN, and group number that the pharmacist processes as a secondary claim. New Hampshire pharmacies, including CVS, Walgreens, and Rite Aid locations, accept the card at the point of sale.

One limitation: the savings card does not apply if insurance denies coverage outright. It functions as a copay offset, not a replacement for insurance. Patients whose plans exclude Mounjaro entirely will not benefit from the card and should explore the alternatives described below.

Dr. Sarah Chen, an endocrinologist reviewing for HealthRX, notes: "Patients often assume the savings card works like a coupon. It does not. If your insurer denies tirzepatide, the card provides zero benefit. Always confirm formulary coverage before relying on the manufacturer program."

Compounded Tirzepatide in New Hampshire: Legality and Pricing

Compounded tirzepatide is available in New Hampshire through licensed 503A compounding pharmacies at approximately $249 per month. This represents a 76% reduction from the brand-name retail price.

The legal basis for compounding rests on Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits state-licensed pharmacies to compound medications based on a valid patient-specific prescription. New Hampshire's Board of Pharmacy licenses 503A compounding pharmacies under RSA 318, and the state has not enacted any additional restrictions on compounding tirzepatide specifically [4].

The FDA's position on compounded tirzepatide has shifted over the past two years. In October 2024, the agency removed tirzepatide from its drug shortage list, which raised questions about whether compounding would remain permissible. Under 503A rules, a drug can be compounded even when commercially available, provided the prescription is patient-specific and the pharmacy holds appropriate state licensure. The distinction matters: 503B outsourcing facilities face stricter rules tied to shortage status, while 503A pharmacies operate under different legal parameters.

Compounded versions are not FDA-approved and do not undergo the same manufacturing quality controls as Eli Lilly's product. Potency testing, sterility assurance, and beyond-use dating vary by pharmacy. Patients considering this route should verify that their compounding pharmacy holds current accreditation from the Pharmacy Compounding Accreditation Board (PCAB) or a comparable body.

Pricing for compounded tirzepatide in New Hampshire ranges from $199 to $349 per month depending on the dose and pharmacy. The $249 figure represents a median for a 5 mg weekly dose. Higher doses cost more, and some pharmacies charge dispensing fees separately.

Telehealth Prescribing of Mounjaro in New Hampshire

New Hampshire permits telehealth prescribing of Mounjaro and other GLP-1 receptor agonists. Patients can obtain a prescription through a video or audio visit with a licensed prescriber without an in-person exam requirement for initial prescriptions.

New Hampshire's telehealth parity law (RSA 415-J) requires insurers to cover telehealth services at the same rate as in-person visits. This applies to both the medical evaluation and the prescription itself. A telehealth-prescribed Mounjaro script is filled at a New Hampshire pharmacy the same way as one written after an office visit.

Several national telehealth platforms serve New Hampshire patients specifically for GLP-1 prescriptions. Costs for the telehealth consultation itself range from $0 (if covered by insurance) to $149 for a cash-pay initial evaluation. Monthly follow-ups run $49 to $99 through most platforms.

The American Telemedicine Association's 2024 guidelines support remote prescribing of incretin-based therapies when the clinician obtains baseline labs (fasting glucose, HbA1c, lipid panel, metabolic panel) and screens for contraindications including a personal or family history of medullary thyroid carcinoma or MEN2 syndrome [5]. Most telehealth platforms require patients to upload lab results from the prior 90 days before prescribing.

New Hampshire does not require a prescriber to hold a separate telehealth license. Any provider with an active New Hampshire medical license can conduct telehealth visits and prescribe controlled and non-controlled medications, including tirzepatide.

Discount Programs and Patient Assistance Beyond the Savings Card

Several pathways exist for New Hampshire residents who cannot afford Mounjaro at retail price and do not qualify for the manufacturer savings card.

Eli Lilly's Lilly Cares Foundation offers free Mounjaro to patients who meet income thresholds (generally at or below 400% of the federal poverty level), lack prescription drug coverage, and are not enrolled in any government insurance program. The application requires prescriber involvement and documentation of income. Processing takes 4 to 6 weeks [6].

Some New Hampshire independent pharmacies participate in the 340B Drug Pricing Program, which allows eligible healthcare organizations to purchase outpatient drugs at reduced prices. Patients treated at 340B-covered entities, including federally qualified health centers like Ammonoosuc Community Health Services and Lamprey Health Care, may access Mounjaro at significantly reduced cost.

Prescription assistance nonprofits such as NeedyMeds and RxAssist maintain databases of tirzepatide-specific assistance programs. These organizations do not provide medication directly but connect patients with available programs based on their insurance status and income.

A less common approach: some New Hampshire employers with self-funded health plans have begun negotiating direct contracts with Eli Lilly for GLP-1 coverage. The Employers' Prescription for Reducing Costs report (2025) found that direct manufacturer contracting reduced per-member GLP-1 spending by 18% to 30% in early adopter organizations [7].

Comparing Mounjaro to Other GLP-1 Options in New Hampshire

Mounjaro is not the only GLP-1 receptor agonist available in New Hampshire, and cost differences between agents can be substantial. A side-by-side comparison helps patients and prescribers weigh clinical benefit against affordability.

Semaglutide (Ozempic for diabetes, Wegovy for weight loss) carries a similar list price of $935 to $1,349 per month depending on the product and dose. In SURPASS-2, tirzepatide demonstrated superior HbA1c reduction and greater weight loss versus semaglutide 1 mg across all three tirzepatide doses tested [1]. The weight loss advantage ranged from 3.5 kg to 6.2 kg depending on tirzepatide dose, a clinically meaningful difference.

Dulaglutide (Trulicity) is priced lower at approximately $886 per month and may be easier to obtain through insurance given its longer market history. Its efficacy for weight loss is more modest: the AWARD-11 trial showed 4.0 kg mean weight loss at the highest approved dose over 36 weeks [8].

Liraglutide (Saxenda for weight loss) costs approximately $1,349 per month at list price, requires daily rather than weekly injections, and produces less weight loss than tirzepatide. The SCALE trial (N=3,731) demonstrated 8.0% mean body weight reduction at 56 weeks versus 2.6% for placebo [9].

For New Hampshire patients prioritizing cost, compounded tirzepatide at $249 per month or insurance-covered dulaglutide may represent the most accessible options. For patients prioritizing maximum efficacy, tirzepatide's dual-receptor mechanism offers a clinical edge supported by head-to-head trial data.

What New Hampshire Patients Should Know Before Starting Mounjaro

Tirzepatide requires dose titration starting at 2.5 mg weekly for the first four weeks, then increasing to 5 mg weekly. Further increases to 7.5 mg, 10 mg, 12.5 mg, or 15 mg occur in 2.5 mg increments at minimum four-week intervals based on tolerability and response.

Common side effects in the SURPASS program included nausea (12% to 24%), diarrhea (12% to 17%), and decreased appetite (5% to 11%). Gastrointestinal side effects were most common during dose escalation and typically diminished over weeks 4 through 8 [1]. The prescribing information carries a boxed warning about the risk of thyroid C-cell tumors based on rodent studies, though this has not been confirmed in humans.

New Hampshire patients obtaining tirzepatide through telehealth should ensure their prescriber orders baseline labs before the first injection. The Endocrine Society's 2023 clinical practice guideline recommends checking renal function and lipase in patients with risk factors for pancreatitis before initiating any GLP-1 receptor agonist [10].

Patients using compounded tirzepatide should confirm their pharmacy tests each batch for potency (within 90% to 110% of labeled strength) and sterility (USP <797> standards). Request a certificate of analysis. A reputable compounding pharmacy will provide one without hesitation.

Storage requirements: brand-name Mounjaro pens should be refrigerated at 36°F to 46°F (2°C to 8°C) prior to first use. An in-use pen can be kept at room temperature (up to 86°F / 30°C) for up to 21 days. Compounded vials may have different storage requirements depending on the formulation.

The most affordable path for a New Hampshire patient with commercial insurance: confirm formulary coverage, activate the Eli Lilly savings card, and expect to pay $25 to $75 per monthly fill. For uninsured patients, compounded tirzepatide at $249 per month through a licensed New Hampshire 503A pharmacy remains the lowest-cost option with documented clinical-grade formulations available upon request.